Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
Loneliness and social isolation linked to heightened risk of death in those with cancer
2.
Slowdown in progress found with cancer survival in England and Wales
3.
New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.
4.
In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.
5.
Year in Review: Multiple Myeloma
1.
Understanding the Importance of CA125: A Comprehensive Guide
2.
The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape
3.
The Future of Hemophilia Treatment: Long-Acting Therapies and Gene Editing
4.
The Mystery of Carotid Body Tumors: The Facts You Need to Know
5.
Case Study: Personalized Medicine Based on Genetic Profiling in Oncology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge